Literature DB >> 23551765

Refractory Henoch-Schönlein purpura: atypical aetiology and management.

Amr El-Husseini1, Ahmed Ahmed, Alberto Sabucedo, Edward Fabulo.   

Abstract

BACKGROUND: A 27-year-old white male was referred with recently diagnosed refractory Henoch-Schönlein purpura nephritis (HSPN). He had a past medical history of hypertension of four years duration and was prescribed lisinopril. He was switched from a brand to a generic lisinopril two days before the onset of first symptoms. On two occasions symptoms had worsened while trying to switch back to the generic drug. He had 9 g/day protein in his urine with haematuria and serum creatinine was up to 123.76 µmol/l (normal value < 106 µmol/l). TREATMENT: The patient underwent two renal biopsies; the first was carried out early after having HSP symptoms and the second was performed a month later. The first biopsy showed mild segmental endocapillary hypercellularity with IgA deposits consistent with HSPN. The second biopsy showed proliferative IgA nephropathy with focal active cellular crescent formation in 38% of the glomeruli.
RESULTS: He did not respond to steroids, cyclophosphamide and plamapheresis. However, his renal and extra-renal manifestations eventually improved after he had received three doses of 1,000 mg rituximab by infusion, two weeks apart.
CONCLUSION: Rituximab might be efficacious in treatment of hspn, more studies are needed to assess long-term safetey and efficacy.
© 2013 European Dialysis and Transplant Nurses Association/European Renal Care Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551765     DOI: 10.1111/j.1755-6686.2013.12007.x

Source DB:  PubMed          Journal:  J Ren Care        ISSN: 1755-6678


  7 in total

Review 1.  B Cells, Antibodies, and More.

Authors:  William Hoffman; Fadi G Lakkis; Geetha Chalasani
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

Review 2.  Management of Small Vessel Vasculitides.

Authors:  Giuseppe Lopalco; Donato Rigante; Vincenzo Venerito; Giacomo Emmi; Maria Grazia Anelli; Giovanni Lapadula; Florenzo Iannone; Luca Cantarini
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

3.  Successful outcome of a corticodependent henoch-schönlein purpura adult with rituximab.

Authors:  Taylor Pindi Sala; Jean-Marie Michot; Renaud Snanoudj; Marion Dollat; Emmanuel Estève; Bernadette Marie; Yacine Taoufik; Jean-François Delfraissy; Thierry Lazure; Olivier Lambotte
Journal:  Case Rep Med       Date:  2014-04-01

4.  What is new in the management of rapidly progressive glomerulonephritis?

Authors:  George H B Greenhall; Alan D Salama
Journal:  Clin Kidney J       Date:  2015-02-19

5.  B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis.

Authors:  Sigrid Lundberg; Emelie Westergren; Jessica Smolander; Annette Bruchfeld
Journal:  Clin Kidney J       Date:  2016-12-13

Review 6.  Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature.

Authors:  Courtney B Crayne; Esraa Eloseily; Melissa L Mannion; Saji P Azerf; Peter Weiser; Timothy Beukelman; Matthew L Stoll; Daniel I Feig; T Prescott Atkinson; Randy Quentin Cron
Journal:  Pediatr Rheumatol Online J       Date:  2018-11-14       Impact factor: 3.054

7.  Long-Term Therapeutic Plasma Exchange to Prevent End-Stage Kidney Disease in Adult Severe Resistant Henoch-Schonlein Purpura Nephritis.

Authors:  Patrick Hamilton; Olumide Ogundare; Ammar Raza; Arvind Ponnusamy; Julie Gorton; Hana Alachkar; Jamil Choudhury; Jonathan Barratt; Philip A Kalra
Journal:  Case Rep Nephrol       Date:  2015-11-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.